Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

CBD may help heavy cannabis users use less THC

NCT ID NCT07471347

Knowledge-focused Sponsor: King's College London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether cannabidiol (CBD) can reduce the amount of THC heavy cannabis users need to feel intoxicated. About 30 adults who use cannabis heavily will take a single dose of CBD or a placebo, then inhale THC using a vaporiser and decide when they've had enough. Researchers will measure how much THC they use, along with mood, thinking, and physical effects, to better understand cannabis tolerance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults, between 18 and 45 years old 2. Heavy and frequent cannabis user: using 7-14 grams of high potency cannabis per week over the past month, and using cannabis on at least 5 days per week over the past month 3. Positive urine drug screen (UDS) for cannabis 4. Willing to abstain from cannabis use for 4 hours before any experimental session. 5. Willing to eat two non-vegan full-fat yoghurts to aid drug absorption 6. Providing written informed consent. Exclusion Criteria: 1. Dependent use of alcohol or illicit drugs (apart from cannabis or tobacco/nicotine) 2. Not able to provide a UDS which is negative for illicit drugs (apart from cannabis) 3. Not able to provide a negative alcohol breath test 4. Personal or family history (first-degree) of psychosis or mania 5. Currently prescribed antidepressant, mood-stabilising, antipsychotic or stimulant medication, or regular medication for a significant medical condition (e.g. antihypertensives, anticonvulsants, anticoagulants, or immunosuppressants) 6. Diagnosis of a major medical or psychiatric illness that the study doctor considers inappropriate for the purposes of this study 7. Female participants who are pregnant or mothers who are lactating 8. Not willing to use an adequate form of contraception for the duration of the study 9. Participant in another experimental medicine study or clinical trial within the past three months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis intoxication are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cannabis dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cannabis intoxication

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • King's Clinical Research Facility

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.